Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254314 | 0.82 | LMNA (0.42) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL898733 | 0.81 | HPGD (0.52) | ALDH1A1KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL29853520 | 0.81 | HPGD (0.52) | ALDH1A1KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL2742615 | 0.80 | HSD17B10 (0.68) | HPGDLMNAHSD17B10POLB | |
| SCHEMBL11780219 | 0.79 | RXFP1 (0.59) | ALDH1A1KMT2AMEN1LMNARXFP1 | |
| SCHEMBL10624636 | 0.78 | HSD17B10 (0.49) | MEN1HPGDHSD17B10HDAC1POLB | |
| Bromide SCHEMBL29853696 | 0.78 | HSD17B10 (0.66) | HPGDLMNAHSD17B10POLB | |
| SCHEMBL1097014 | 0.78 | HSD17B10 (0.49) | ALDH1A1HPGDHSD17B10HDAC1POLB | |
| SCHEMBL3594266 | 0.76 | MEN1 (0.47) | ALDH1A1KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL3822251 | 0.76 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10HDAC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350043-B2 | Azinone and diazinone V3 inhibitors for depression and stress disorders | PHARMACOPEIA, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2006133242-A2 | AZINONE AND DIAZINONE V3 INHIBITORS FOR DEPRESSION AND STRESS DISORDERS | PHARMACOPEIA, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037822-A1 | Azinone and diazinone V3 inhibitors for depression and stress disorders | HTR3C, HTR3A, AZI2 | ALDH1A1 200/4885KMT2A 1562/4885MEN1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.